Design of anticancer lysophosphatidic acid agonists and antagonists

Future Medicinal Chemistry

Volumn 6, Issue 8, 2014, Pages 871-883

  Parrill, Abby L ^a  

^a University of Memphis   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETASTATIC AGENT; ANTINEOPLASTIC AGENT; BMS 986020; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDIC ACID AGONIST; LYSOPHOSPHATIDIC ACID ANTAGONIST; LYSOPHOSPHATIDIC ACID RECEPTOR; SAR 100842; SCAFFOLD PROTEIN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1; LYSOPHOSPHOLIPID;

ABSORPTION; ANTINEOPLASTIC ACTIVITY; CANCER PAIN; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; COLORECTAL CANCER; CRYPT CELL; DRUG DESIGN; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HUMAN; IN VIVO STUDY; LUNG CANCER; LUNG FIBROSIS; METASTASIS; METASTASIS INHIBITION; NEUROPATHIC PAIN; OVARY CANCER; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON; PRIORITY JOURNAL; RADIOTHERAPY; RECEPTOR OCCUPANCY; REVIEW; STRUCTURE ACTIVITY RELATION; TUMOR GROWTH; TUMOR XENOGRAFT; AGONISTS; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; METABOLISM; NEOPLASMS; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; HUMANS; LYSOPHOSPHOLIPIDS; NEOPLASMS; RECEPTORS, LYSOPHOSPHATIDIC ACID; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84903280095     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.14.52     Document Type: Review

References (74)

1. Mutoh T, Rivera R, Chun J. Insights into the pharmacological relevance of lysophospholipid receptors. Br. J. Pharmacol. 165(4), 829-844 (2012).
2. Parrill AL, Tigyi G. Integrating the puzzle pieces: the current atomistic picture of phospholipid-G protein coupled receptor interactions. Biochim. Biophys. Acta 1831(1), 2-12 (2013).
3. Brindley DN, Lin FT, Tigyi GJ. Role of the autotaxinlysophosphatidate axis in cancer resistance to chemotherapy and radiotherapy. Biochim. Biophys. Acta 1831(1), 74-85 (2013).
4. Moolenaar WH, Perrakis A. Insights into autotaxin: how to produce and present a lipid mediator. Nat. Rev. Mol. Cell Biol. 12(10), 674-679 (2011).
5. Umezu-Goto M, Kishi Y, Taira A et al. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J. Cell Biol. 158(2), 227-233 (2002).
6. Tokumura A, Majima E, Kariya Y et al. Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J. Biol. Chem. 277(42), 39436-39442 (2002). (Pubitemid 35190918)
7. Hiramatsu T, Sonoda H, Takanezawa Y et al. Biochemical and molecular characterization of two phosphatidic acidselective phospholipase A1s, mPA-PLA1alpha and mPAPLA1beta. J. Biol. Chem. 278(49), 49438-49447 (2003).
8. Foell JL, Hesse M, Volkmer I, Schmiedel BJ, Neumann I, Staege MS. Membrane-associated phospholipase A1 beta (LIPI) Is an Ewing tumour-associated cancer/testis antigen. Pediatr Blood Cancer 51(2), 228-234 (2008). (Pubitemid 351877042)
9. Schmiedel BJ, Hutter C, Hesse M, Staege MS. Expression of multiple membrane-associated phospholipase A1 beta transcript variants and lysophosphatidic acid receptors in Ewing tumor cells. Mol. Biol. Rep. 38(7), 4619-4628 (2011).
10. Yung YC, Stoddard NC, Chun J. LPA receptor signaling: pharmacology, physiology, and pathophysiology. J. Lipid Res. doi:10.1194/jlr.R046458 (2014) (Epub ahead of print).
11. Lv GM, Li P, Wang WD, Wang Sh K, Chen JF, Gong YL. Lysophosphatidic acid (LPA) and endothelial differentiation gene (Edg) receptors in human pancreatic cancer. J. Surg. Oncol. 104(6), 685-691 (2011).
12. Gotoh M, Fujiwara Y, Yue J et al. Controlling cancer through the autotaxin-lysophosphatidic acid receptor axis. Biochem. Soc. Trans. 40(1), 31-36 (2012).
13. Willier S, Butt E, Grunewald TG. Lysophosphatidic acid (LPA) signalling in cell migration and cancer invasion: a focussed review and analysis of LPA receptor gene expression on the basis of more than 1700 cancer microarrays. Biol. Cell 105(8), 317-333 (2013).
14. Schleicher SM, Thotala DK, Linkous AG et al. Autotaxin and LPA receptors represent potential molecular targets for the radiosensitization of murine glioma through effects on tumor vasculature. PLoS ONE 6(7), e22182 (2011).
15. Samadi N, Bekele R, Capatos D, Venkatraman G, Sariahmetoglu M, Brindley DN. Regulation of lysophosphatidate signaling by autotaxin and lipid phosphate phosphatases with respect to tumor progression, angiogenesis, metastasis and chemo-resistance. Biochimie 93(1), 61-70 (2011).
16. Houben AJ, Moolenaar WH. Autotaxin and LPA receptor signaling in cancer. Cancer Metastasis Rev. 30(3-4), 557-565 (2011).
17. Okudaira S, Yukiura H, Aoki J. Biological roles of lysophosphatidic acid signaling through its production by autotaxin. Biochimie 92(6), 698-706 (2010).
18. Xu XY, Prestwich GD. Inhibition of tumor growth and angiogenesis by a lysophosphatidic acid antagonist in an engineered three-dimensional lung cancer xenograft model. Cancer Am. Cancer. Soc. 116(7), 1739-1750 (2010).
19. Zhang H, Xu X, Gajewiak J et al. Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo. Cancer Res. 69(13), 5441-5449 (2009).
20. Xu X, Yang G, Zhang H, Prestwich GD. Evaluating dual activity LPA receptor pan-antagonist/autotaxin inhibitors as anti-cancer agents in vivo using engineered human tumors. Prostaglandins Other Lipid Mediat. 89(3-4), 140-146 (2009).
21. Komachi M, Tomura H, Malchinkhuu E et al. LPA1 receptors mediate stimulation, whereas LPA2 receptors mediate inhibition, of migration of pancreatic cancer cells in response to lysophosphatidic acid and malignant ascites. Carcinogenesis 30(3), 457-465 (2009).
22. Lee Z, Cheng CT, Zhang H et al. Role of LPA4/p2y9/GPR23 in negative regulation of cell motility. Mol. Biol. Cell 19(12), 5435-5445 (2008).
23. Jongsma M, Matas-Rico E, Rzadkowski A, Jalink K, Moolenaar WH. LPA is a chemorepellent for B16 melanoma cells: action through the cAMP-elevating LPA5 receptor. PLoS ONE 6(12), e29260 (2011).
24. Pan HL, Zhang YQ, Zhao ZQ. Involvement of lysophosphatidic acid in bone cancer pain by potentiation of TRPV1 via PKC epsilon pathway in dorsal root ganglion neurons. Mol. Pain 6, 85 (2010).
25. Xiang SY, Dusaban SS, Brown JH. Lysophospholipid receptor activation of RhoA and lipid signaling pathways. Biochim. Biophys. Acta 1831(1), 213-222 (2013).
26. Kitzing TM, Sahadevan AS, Brandt DT et al. Positive feedback between Dia1, LARG, and RhoA regulates cell morphology and invasion. Genes Dev. 21(12), 1478-1483 (2007). (Pubitemid 46955720)
27. Shida D, Kitayama J, Yamaguchi H et al. Dual mode regulation of migration by lysophosphatidic acid in human gastric cancer cells. Exp. Cell Res. 301(2), 168-178 (2004). (Pubitemid 39504970)
28. Shida D, Kitayama J, Yamaguchi H et al. Lysophosphatidic acid (LPA) enhances the metastatic potential of human colon carcinoma DLD1 cells through LPA1. Cancer Res. 63(7), 1706-1711 (2003). (Pubitemid 36373664)
29. Marshall JC, Collins J, Marino N, Steeg P. The Nm23-H1 metastasis suppressor as a translational target. Eur. J. Cancer 46(7), 1278-1282 (2010).
30. Peyruchaud O, Leblanc R, David M. Pleiotropic activity of lysophosphatidic acid in bone metastasis. Biochim. Biophys. Acta 1831(1), 99-104 (2013).
31. Tager AM, LaCamera P, Shea BS et al. The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat. Med. 14(1), 45-54 (2008).
32. Budd DC, Qian Y. Development of lysophosphatidic acid pathway modulators as therapies for fibrosis. Future Med. Chem. 5(16), 1935-1952 (2013).
33. Ward Y, Lake R, Martin PL et al. CD97 amplifies LPA receptor signaling and promotes thyroid cancer progression in a mouse model. Oncogene 32(22), 2726-2738 (2013).
34. Ward Y, Lake R, Yin JJ et al. LPA receptor heterodimerizes with CD97 to amplify LPA-initiated RHO-dependent signaling and invasion in prostate cancer cells. Cancer Res. 71(23), 7301-7311 (2011).
35. Xu J, Lai YJ, Lin WC, Lin FT. TRIP6 enhances lysophosphatidic acid-induced cell migration by interacting with the lysophosphatidic acid 2 receptor. J. Biol. Chem. 279(11), 10459-10468 (2004). (Pubitemid 38372655)
36. Willier S, Butt E, Richter GH, Burdach S, Grunewald TG. Defining the role of TRIP6 in cell physiology and cancer. Biol. Cell 103(12), 573-591 (2011).
37. Lin S, Wang D, Iyer S et al. The absence of LPA2 attenuates tumor formation in an experimental model of colitisassociated cancer. Gastroenterology 136(5), 1711-1720 (2009).
38. Lee SJ, Yun CC. Colorectal cancer cells-proliferation, survival and invasion by lysophosphatidic acid. Int. J. Biochem. Cell Biol. 42(12), 1907-1910 (2010).
39. Deng W, Balazs L, Wang DA, Van Middlesworth L, Tigyi G, Johnson LR. Lysophosphatidic acid protects and rescues intestinal epithelial cells from radiation-and chemotherapyinduced apoptosis. Gastroenterology 123(1), 206-216 (2002). (Pubitemid 34747541)
40. Kiss GN, Lee SC, Fells JI et al. Mitigation of radiation injury by selective stimulation of the LPA(2) receptor. Biochim. Biophys. Acta 1831(1), 117-125 (2013).
41. Hurst JH, Hooks SB. Lysophosphatidic acid stimulates cell growth by different mechanisms in SKOV-3 and Caov-3 ovarian cancer cells: distinct roles for Gi-and Rho-dependent pathways. Pharmacology 83(6), 333-347 (2009).
42. Yu S, Murph MM, Lu Y et al. Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J. Natl Cancer Inst. 100(22), 1630-1642 (2008).
43. Goldsmith ZG, Ha JH, Jayaraman M, Dhanasekaran DN. Lysophosphatidic acid stimulates the proliferation of ovarian cancer cells via the gep proto-oncogene Galpha(12). Genes Cancer 2(5), 563-575 (2011).
44. Pancione M, Sabatino L, Fucci A et al. Epigenetic silencing of peroxisome proliferator-activated receptor gamma is a biomarker for colorectal cancer progression and adverse patients' outcome. PLoS ONE 5(12), e14229 (2010).
45. Tsukahara T, Hanazawa S, Kobayashi T, Iwamoto Y, Murakami-Murofushi K. Cyclic phosphatidic acid decreases proliferation and survival of colon cancer cells by inhibiting peroxisome proliferator-activated receptor gamma. Prostaglandins Other Lipid Mediat. 93(3-4), 126-133 (2010).
46. Endo T, Kano K, Motoki R et al. Lysophosphatidylmethanol is a pan lysophosphatidic acid receptor agonist and is produced by autotaxin in blood. J. Biochem. 146(2), 283-293 (2009).
47. Jiang G, Inoue A, Aoki J, Prestwich GD. Phosphorothioate analogs of sn-2 radyl lysophosphatidic acid (LPA): metabolically stabilized LPA receptor agonists. Bioorg. Med. Chem. Lett. 23(6), 1865-1869 (2013).
48. Valentine WJ, Fells JI, Perygin DH et al. Subtype-specific residues involved in ligand activation of the endothelial differentiation gene family lysophosphatidic acid receptors. J. Biol. Chem. 283(18), 12175-12187 (2008).
49. Yanagida K, Kurikawa Y, Shimizu T, Ishii S. Current progress in non-Edg family LPA receptor research. Biochim. Biophys. Acta 1831(1), 33-41 (2013).
50. East JE, Carter KM, Kennedy PC et al. Development of a phosphatase-resistant, L-tyrosine derived LPA1/LPA3 dual antagonist. MedChemComm 2(4), 325-330 (2011).
51. Durgam GG, Virag T, Walker MD et al. Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARgamma, and inhibitors of autotaxin. J. Med. Chem. 48(15), 4919-4930 (2005). (Pubitemid 41033134)
52. Fells JI, Tsukahara R, Fujiwara Y et al. Identification of nonlipid LPA3 antagonists by virtual screening. Bioorg. Med. Chem. 16(11), 6207-6217 (2008). (Pubitemid 351758823)
53. Fells JI, Tsukahara R, Liu J, Tigyi G, Parrill AL. Structurebased drug design identifies novel LPA3 antagonists. Bioorg. Med. Chem. 17(21), 7457-7464 (2009).
54. Swaney JS, Chapman C, Correa LD et al. A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model. Br. J. Pharmacol. 160(7), 1699-1713 (2010).
55. Qian Y, Hamilton M, Sidduri A et al. Discovery of highly selective and orally active lysophosphatidic acid receptor-1 antagonists with potent activity on human lung fibroblasts. J. Med. Chem. 55(17), 7920-7939 (2012).
56. Ren Y, Guo L, Tang X et al. Comparing the differential effects of LPA on the barrier function of human pulmonary endothelial cells. Microvasc. Res. 85, 59-67 (2013).
57. Ohta H, Sato K, Murata N et al. Ki16425, a subtypeselective antagonist for EDG-family lysophosphatidic acid receptors. Mol. Pharmacol. 64(4), 994-1005 (2003). (Pubitemid 37153068)
58. Kiss GN, Fells JI, Gupte R et al. Virtual screening for LPA2-specific agonists identifies a nonlipid compound with antiapoptotic actions. Mol. Pharmacol. 82(6), 1162-1173 (2012).
59. Xu Y, Jiang GW, Tsukahara R, Fujiwara Y, Tigyi G, Prestwich GD. Phosphonothioate and fluoromethylene phosphonate analogues of cyclic phosphatidic acid: Novel antagonists of lysophosphatidic acid receptors. J. Med. Chem. 49(17), 5309-5315 (2006). (Pubitemid 44262034)
60. Altman MK, Gopal V, Jia W et al. Targeting melanoma growth and viability reveals dualistic functionality of the phosphonothionate analogue of carba cyclic phosphatidic acid. Mol. Cancer 9, 140 (2010).
61. Xue J, Gan L, Li X et al. Effects of lysophosphatidic acid and its receptors LPA(1/3) on radiation pneumonitis. Oncol. Rep. 24(6), 1515-1520 (2010).
62. Gan L, Xue JX, Li X et al. Blockade of lysophosphatidic acid receptors LPAR1/3 ameliorates lung fibrosis induced by irradiation. Biochem. Biophys. Res. Commun. 409(1), 7-13 (2011).
63. Swaney JS, Chapman C, Correa LD et al. Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist. J. Pharmacol. Exp. Ther. 336(3), 693-700 (2011).
64. Komachi M, Sato K, Tobo M et al. Orally active lysophosphatidic acid receptor antagonist attenuates pancreatic cancer invasion and metastasis in vivo. Cancer Sci. 103(6), 1099-1104 (2012).
65. David M, Ribeiro J, Descotes F et al. Targeting lysophosphatidic acid receptor type 1 with Debio 0719 inhibits spontaneous metastasis dissemination of breast cancer cells independently of cell proliferation and angiogenesis. Int. J. Oncol. 40(4), 1133-1141 (2012).
66. ClinicalTrials.gov. www.clinicaltrials.gov
67. Graber K. At the frontiers of lung fibrosis therapy. Nat. Biotech. 31(9), 781-783 (2013).
68. ClinicalTrials.gov: NCT01766817. http://clinicaltrials.gov/show/ NCT01766817
69. ClinicalTrials.gov: NCT02068053. http://clinicaltrials.gov/ct2/show/ NCT02068053
70. ClinicalTrials.gov: NCT02017730. http://clinicaltrials.gov/ct2/show/ NCT02017730
71. ClinicalTrials.gov: NCT01651143. http://clinicaltrials.gov/show/ NCT01651143
72. Vidot S, Witham J, Agarwal R et al. Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells. Cell Signal. 22(6), 926-935 (2010).
73. Samadi N, Bekele RT, Goping IS, Schang LM, Brindley DN. Lysophosphatidate induces chemo-resistance by releasing breast cancer cells from taxol-induced mitotic arrest. PLoS ONE 6(5), e20608 (2011).
74. Su SC, Hu X, Kenney PA et al. Autotaxin-lysophosphatidic acid signaling axis mediates tumorigenesis and development of acquired resistance to sunitinib in renal cell carcinoma. Clin. Cancer Res. 19(23), 6461-6472 (2013).